Telix's Pixclara wins FDA approval as first glioma FET-PET agent

Telix Pharmaceuticals has received US Food and Drug Administration approval for Pixclara (floretyrosine F 18), making it the first FDA-approved fluoroethyltyrosine PET imaging drug for glioma. The approval covers adults and paediatric patients aged one month and older, and is indicated for differentiating recurrent or progressive glioma from treatment-related change when used alongside other diagnostic assessments.

The distinction between tumour recurrence and post-treatment effects such as radiation necrosis has long challenged neuro-oncologists. Conventional MRI can be ambiguous in this setting, and clinicians have historically relied on clinical judgement or invasive biopsy to resolve the uncertainty. FET-PET, which targets L-type amino acid transporters overexpressed in glioma cells, offers a functional read-out that MRI cannot. The technique has featured in international clinical practice guidelines, including the NCCN and a joint 2025 Lancet Oncology statement from EANM, EANO, SNMMI and RANO, but has until now lacked an FDA-approved product in the US market.

Clinical and commercial context

Safety data from 382 patients evaluated during the approval programme showed a favourable profile. The most common adverse reaction was headache, occurring in 0.5% of patients. Nausea, injection-site reaction, fatigue and malaise were each reported in fewer than 0.5% of patients. Telix notes that, as with all PET agents, image misinterpretation is a risk and results should be correlated with histopathology and clinical history.

Kevin Richardson, chief executive of Telix Precision Medicine, said the approval would "provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning." Patrick Wen, a neuro-oncologist at Mass General Brigham Cancer Institute, described having an FDA-approved FET-PET product as "a very positive step forward for brain cancer imaging and treatment planning."

Gliomas account for approximately 30% of all brain and central nervous system tumours and around 80% of malignant brain tumours. Roughly 24,000 new cases are diagnosed in the US each year, a patient population that has lacked access to guideline-recommended FET-PET imaging through an approved commercial product.

Theranostics pipeline and next steps

Pixclara sits alongside Illuccix and Gozellix, Telix's two approved prostate imaging agents, in a growing precision diagnostics franchise that the Melbourne-headquartered company describes as the commercial anchor for its broader theranostics strategy. The company has three late-stage therapeutic candidates in pivotal trials targeting prostate cancer, recurrent glioblastoma and kidney cancer, none of which yet carries marketing authorisation.

The glioma indication may broaden further. Pixclara is currently being evaluated in a Phase 3 registrational study as a diagnostic tool for brain metastases, with the IND cleared by the FDA in August 2026. If that readout is positive, Telix would have a rare radiopharmaceutical platform spanning two distinct CNS indications.

The competitive landscape for radiopharmaceutical diagnostics is becoming more active, with several large pharmaceutical groups investing in theranostics platforms. Novartis's acquisition of AAA and the subsequent commercial success of Lutathera and Pluvicto have drawn renewed industry attention to the sector. Telix's dual-listed status on the ASX and NASDAQ, combined with an expanding approved-product base, positions it as one of the more substantive independent players in the space outside the major pharma groups.